Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

PubWeight™: 2.22‹?› | Rank: Top 2%

🔗 View Article (PMC 2646906)

Published in J Hepatol on May 20, 2008

Authors

Myron Schwartz1, Igor Dvorchik, Sasan Roayaie, M Isabel Fiel, Sidney Finkelstein, J Wallis Marsh, John A Martignetti, Josep M Llovet

Author Affiliations

1: Mount Sinai Liver Cancer Program, Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, New York, NY 10029, USA. myron.schwartz@mountsinai.org

Articles citing this

Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66

Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14

Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl (2011) 0.90

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation. Int J Med Sci (2014) 0.87

Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83

Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One (2011) 0.80

Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol (2015) 0.77

Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Sci Rep (2016) 0.75

Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75

Molecular markers for predicting hepatocellular carcinoma recurrence following liver transplantation. Liver Transpl (2008) 0.75

Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.75

Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant (2016) 0.75

Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation? J Hepatol (2008) 0.75

Articles cited by this

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Cancer genes and the pathways they control. Nat Med (2004) 24.22

Hepatocellular carcinoma. Lancet (2003) 22.54

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14

Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10

Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03

Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85

Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res (2004) 1.37

Liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.24

Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg (2007) 1.18

Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol (2005) 1.08

Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl (2003) 1.08

Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology (2003) 1.03

Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery (2004) 0.99

Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl (2004) 0.98

Predicting individual outcomes in hepatocellular carcinoma. Lancet (2004) 0.95

Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut (2004) 0.94

Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma. Mod Pathol (2003) 0.90

Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology (2001) 0.90

Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg (2001) 0.87

Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation. Hum Pathol (2002) 0.87

Molecular analysis of primary and recurrent giant cell tumors of bone. Cancer Genet Cytogenet (2005) 0.85

Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol (2005) 0.85

Gene expression profiles in hepatocellular carcinoma: not yet there. J Hepatol (2004) 0.85

Tumor suppressor gene allelic loss profiles of the variants of papillary thyroid carcinoma. Diagn Mol Pathol (2004) 0.84

Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13. Hum Pathol (2004) 0.82

Articles by these authors

Hepatocellular carcinoma. Lancet (2012) 18.09

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62

Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl (2003) 3.11

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13

Major achievements in hepatocellular carcinoma. Lancet (2009) 2.10

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90

Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?--yes. J Hepatol (2005) 1.89

Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet (2003) 1.86

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86

Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg (2010) 1.85

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85

Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84

Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl (2005) 1.79

Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77

Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin Transplant (2007) 1.70

Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65

Posttransplant biliary complications in the pre- and post-model for end-stage liver disease era. Liver Transpl (2011) 1.63

Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59

Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57

Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet (2007) 1.56

A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecol Oncol (2010) 1.56

Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53

Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52

Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51

Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol (2008) 1.50

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

The first report of homozygous May-Hegglin anomaly E1841K mutation. Eur J Haematol (2011) 1.46

New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44